

# Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

<https://marketpublishers.com/r/C8051F95AC2EN.html>

Date: March 2017

Pages: 53

Price: US\$ 450.00 (Single User License)

ID: C8051F95AC2EN

## Abstracts

Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

This Competitive Intelligence Report about RSV Antibodies, Vaccines & Antivirals provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, small molecules, protein and peptide therapeutics against infection caused by respiratory syncytial virus (RSV) as of March 2017.

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections among young children in the United States and worldwide. Most infants are infected before the age of one, and virtually everyone gets an RSV infection by the age of two. A prophylactic vaccine is not available and specific treatment is limited to the monoclonal antibody Synagis (palivizumab), a candidate for biosimilar conversion in the near future.

RSV infection in the pediatric and adult populations account for more than 300,000 hospitalizations per year in the U.S. In the developing world, RSV is responsible for 30 million cases of acute respiratory tract infection and 200,000 deaths per year. As a result, there is a significant need for novel therapeutics to prevent RSV infection.

The report includes a compilation of currently active projects in development of vaccines, antibodies, small molecules, peptides and proteins targeting respiratory syncytial virus for prophylaxis and treatment of RSV infections. In addition, the report lists company-specific R&D pipelines of RSV Antibodies, Vaccines & Antivirals. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

#### About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

## Contents

### **RSV ANTIBODIES:**

Palivizumab Biosuperiors

Palivizumab Biosimilars

### **RSV ANTIVIRALS:**

Small Molecule Therapeutics

Other RSV Therapeutics

### **RSV VACCINES:**

Live-Attenuated & Whole-Inactivated RSV Vaccines

Virus-Like Particle (VLP) RSV Vaccines

Subunit RSV Vaccines

DNA-/RNA-Based RSV Vaccines

## I would like to order

Product name: Competitor Analysis: Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

Product link: <https://marketpublishers.com/r/C8051F95AC2EN.html>

Price: US\$ 450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C8051F95AC2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

